Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Hodgkin’s Lymphoma | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

Login to access report north_east
Contact sales account_box

The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the label expansion of Adcetris and the approval of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).

CONTENT OVERVIEW

From disease basics to insightful analysis of market dynamics, Hodgkin’s lymphoma | Disease Landscape & Forecast | US and EU5 provides comprehensive disease coverage addressing critical aspects of the Hodgkin’s lymphoma pharmaceutical market based on primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug-treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a topline review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.

WHAT YOU WILL LEARN IN THIS CONTENT

  • How large is the drug-treatable Hodgkin’s lymphoma population and how will drug-treatment rates change over time?
  • What is the current state of treatment in Hodgkin’s lymphoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in Hodgkin’s lymphoma? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?

KEY DRUGS COVERED

Adcetris, Opdivo, Keytruda, Farydak, Rituxan/MabThera

KEY COMPANIES MENTIONED

  • Seattle Genetics
  • Takeda
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis
  • Roche/Genentech
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east